Home > Investor > Looking ahead

Looking ahead

Becoming a strong regional player and the first partnering choice

New products

Expanding the product portfolio will strenghten the growth potential.

There is a pharmaceutical development of 9 new medicinal products/projects.
Organic growth

Grow organically in selected new markets to become a strong regional player with stable, geographically diversified revenues by: 

  • Selective entry into new markets with high growth potential
  • Registering and marketing the Company’s branded pharmaceutical products in other EU countries 
  • Continuing to selectively assess acquisition and strategic partnership opportunities
    • Potential for growth on more than 20 markets having less than 1% current share in sales revenues.
    Market position

    Maintain the Company’s position as a leading Bulgarian pharmaceutical manufacturer with high quality affordable products and improve existing products.
    Follow market needs

    Two new medicinal products have been authorised:- Diclofenac Diethylamine 23.2 mg/g gel (DCP - Denmark, Sweden, Norway, Finland);License:- Paracedol Duo 200 mg/ 500 mg fct (Bulgaria).
    Intra group integration

    Further consolidate and integrate the Group to optimize its cost structure, control entirely the production chain and benefit from potential synergies.